Indianoloa, PA-based Medrad has signed an exclusive two-year agreement to distribute worldwide a cardiovascular MR surface coil developed by W.L. Gore & Associates. The coil combines in a single device a dedicated cardiac coil and a dedicated abdominal
Indianoloa, PA-based Medrad has signed an exclusive two-year agreement to distribute worldwide a cardiovascular MR surface coil developed by W.L. Gore & Associates. The coil combines in a single device a dedicated cardiac coil and a dedicated abdominal coil. Extending from the chest to the bifurcation of the aorta in the pelvic region, the Cardiovascular Array supports the visualization of vascular disease throughout the entire torso in a single scan. The FDA cleared the product, which is compatible with all phased-array versions of the GE Signa 1.5T system and will be available in the U.S. in July. Worldwide distribution will begin next year. Medrad currently distributes another Gore product, the Torso Array surface coil, which was released in November 2000.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.